🔗 Visit the ClinicalTrials.gov page for NCT01175356
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Advances in Risk Classification and Treatment Strategies for Neuroblastoma. | J Clin Oncol | 2015 | 1.19 |
| 2 | An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. | BMC Cancer | 2016 | 0.83 |
| 3 | Genetic discoveries and treatment advances in neuroblastoma. | Curr Opin Pediatr | 2016 | 0.77 |
| 4 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 5 | Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. | Pediatr Blood Cancer | 2016 | 0.75 |